Document Detail

Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
MedLine Citation:
PMID:  22136831     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: There are limited data on the utility of 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) and (18)F-2-deoxy-d-glucose ((18)F-FDG) in the workup of patients with pancreatic neuroendocrine tumors (PNETs). The aim of our study was to determine the accuracy of (18)F-DOPA and (18)F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL).
METHODS: We studied prospectively 69 patients with a diagnosis of vHL and pancreatic lesion(s) using computed tomography (CT), magnetic resonance imaging (MRI), (18)F-FDG, and (18)F-DOPA. Clinical, genetic, and laboratory characteristics were analyzed to determine association with imaging study results.
RESULTS: In sum, 40 patients underwent evaluation by all 4 modalities; 98 PNETs and 55 PNETs were identified on CT and MRI, respectively. Only 11 of the 98 lesions (11%) were positive on (18)F-DOPA and 45 of the 98 (46%) lesions were positive on (18)F-FDG. There were 13 (18)F-DOPA and 26 (18)F-FDG avid extrapancreatic lesions. One patient underwent resection of an (18)F-DOPA avid extrapancreatic lesion in the lung, with pathology demonstrating a NET. There was no association between (18)F-DOPA and (18)F-FDG avidity and tumor size, age, gender, vHL mutation, or serum chromogranin A level.
CONCLUSION: (18)F-FDG and MRI may be adjuncts to CT in identifying PNETs and metastatic disease. (18)F-DOPA has limited value in identifying PNETs in patients with vHL, but may be useful for identifying extrapancreatic NET lesions.
Mio Kitano; Corina Millo; Reza Rahbari; Peter Herscovitch; Krisana Gesuwan; Richard C Webb; Aradhana M Venkatesan; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Naris Nilubol; William M Linehan; Electron Kebebew
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Surgery     Volume:  150     ISSN:  1532-7361     ISO Abbreviation:  Surgery     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-05     Completed Date:  2012-02-06     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  0417347     Medline TA:  Surgery     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1122-8     Citation Subset:  AIM; IM    
Copyright Information:
Published by Mosby, Inc.
Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, 10 Center Drive, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dopamine / analogs & derivatives*,  diagnostic use
Fluorodeoxyglucose F18 / diagnostic use*
Magnetic Resonance Imaging*
Middle Aged
Neuroendocrine Tumors / complications,  diagnosis*
Pancreatic Neoplasms / complications,  diagnosis*
Positron-Emission Tomography
Prospective Studies
Radiopharmaceuticals / diagnostic use*
Tomography, X-Ray Computed
Young Adult
von Hippel-Lindau Disease / complications*
Grant Support
Z01 BC011028-01/BC/NCI NIH HHS; Z01 BC011038-01/BC/NCI NIH HHS; Z01 BC011089-01/BC/NCI NIH HHS; Z99 CA999999/CA/NCI NIH HHS; ZIA BC011286-01/BC/NCI NIH HHS
Reg. No./Substance:
0/Radiopharmaceuticals; 59043-70-8/6-fluorodopamine; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Population-level predictors of persistent hyperparathyroidism.
Next Document:  Zollinger-Ellison syndrome associated with a history of alcohol abuse: Coincidence or consequence?